A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients
Aim To compare 6 months of treatment with bimatoprost and timolol in terms of their hypotensive efficacy and secondary effects, including changes in macular thickness and the inflammatory reaction induced in the anterior chamber. Methods A prospective, randomized, parallel-group trial performed on 3...
Gespeichert in:
| Veröffentlicht in: | Eye (London) 2007-02, Vol.21 (2), p.164-168 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 168 |
|---|---|
| container_issue | 2 |
| container_start_page | 164 |
| container_title | Eye (London) |
| container_volume | 21 |
| creator | Martin, E Martinez-de-la-Casa, J M Garcia-Feijoo, J Troyano, J Larrosa, J M Garcia-Sanchez, J |
| description | Aim
To compare 6 months of treatment with bimatoprost and timolol in terms of their hypotensive efficacy and secondary effects, including changes in macular thickness and the inflammatory reaction induced in the anterior chamber.
Methods
A prospective, randomized, parallel-group trial performed on 30 eyes of 30 patients per group. The main outcome measure was the difference between the IOP value taken between the baseline visit and the 6-month-visit. Macular thickness determined through optical coherence tomography and anterior chamber inflammation estimated using the laser flare meter was also evaluated. Adverse events were recorded during the study period.
Results
Bimatoprost treatment gave rise to a significantly lower mean IOP than timolol in all follow-up visits as from the first month (
P |
| doi_str_mv | 10.1038/sj.eye.6702149 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_218352774</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1207769081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c496t-751b6041f71c80ced79688fc0e52d668507dedf21ffb8355c846b3754a9c89ff3</originalsourceid><addsrcrecordid>eNp1kUtv1DAUhS0EokNhyxJZSLMjqZ34FXZVBRSpEhuQ2EWOc93JkMSD7VSan8M_5ZYJmlVXlny-c1-HkLeclZzV5irtSzhCqTSruGiekQ0XWhVSSPGcbFgjWVFV1c8L8iqlPWMoavaSXHBVIdKwDflzTVUxhTnvqE0JUppgzjR42g2TzeEQQ8qUlaze0odE8zCFMYx0siPYDCjI7Ue6Ox5ChjkND0DB-8FZd_yAjFtGG2neDe7XjJWpnXvq8QvoMNPwTy3QC_G_-RG4H-3iwmTpweYBZ0mvyQtvxwRv1veS_Pj86fvNbXH37cvXm-u7wolG5UJL3ikmuNfcGeag140yxjsGsuqVMpLpHnpfce87U0vpjFBdraWwjTON9_UleX-qizv_XiDldh-WOGPLtuLoqLQWCJUnyOFhUgTfHiIeKh5bztrHQNq0bzGQdg0EDe_Wqks3QX_G1wQQ2K6ATc6OPtrZDenMGSmMkhK5qxOXUJrvIZ7He6L1XytdpcE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218352774</pqid></control><display><type>article</type><title>A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Martin, E ; Martinez-de-la-Casa, J M ; Garcia-Feijoo, J ; Troyano, J ; Larrosa, J M ; Garcia-Sanchez, J</creator><creatorcontrib>Martin, E ; Martinez-de-la-Casa, J M ; Garcia-Feijoo, J ; Troyano, J ; Larrosa, J M ; Garcia-Sanchez, J</creatorcontrib><description>Aim
To compare 6 months of treatment with bimatoprost and timolol in terms of their hypotensive efficacy and secondary effects, including changes in macular thickness and the inflammatory reaction induced in the anterior chamber.
Methods
A prospective, randomized, parallel-group trial performed on 30 eyes of 30 patients per group. The main outcome measure was the difference between the IOP value taken between the baseline visit and the 6-month-visit. Macular thickness determined through optical coherence tomography and anterior chamber inflammation estimated using the laser flare meter was also evaluated. Adverse events were recorded during the study period.
Results
Bimatoprost treatment gave rise to a significantly lower mean IOP than timolol in all follow-up visits as from the first month (
P
<0.05). Bimatoprost achieved high percentage IOP reductions from baseline in a significantly higher proportion of patients (
P
<0.05). Macular thickness and anterior chamber flare failed to vary significantly both between the two groups and within each group during the 6-month evaluation (
P
>0.05).
Conclusions
Bimatoprost 0.03% once daily showed a greater efficacy then timolol 0.05% twice daily in patients with elevated IOP. No significant differences were detected in macular thickness or anterior uveitis using optical coherence tomography and laser flare photometry.</description><identifier>ISSN: 0950-222X</identifier><identifier>EISSN: 1476-5454</identifier><identifier>DOI: 10.1038/sj.eye.6702149</identifier><identifier>PMID: 16254590</identifier><identifier>CODEN: EYEEEC</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adult ; Amides - adverse effects ; Amides - therapeutic use ; Anterior Chamber - drug effects ; Anterior Chamber - pathology ; Antihypertensive Agents - adverse effects ; Antihypertensive Agents - therapeutic use ; Bimatoprost ; Biological and medical sciences ; clinical-study ; Cloprostenol - adverse effects ; Cloprostenol - analogs & derivatives ; Cloprostenol - therapeutic use ; Glaucoma ; Glaucoma and intraocular pressure ; Glaucoma, Open-Angle - drug therapy ; Glaucoma, Open-Angle - pathology ; Humans ; Intraocular Pressure - drug effects ; Laboratory Medicine ; Lipids - adverse effects ; Lipids - therapeutic use ; Macula Lutea - drug effects ; Macula Lutea - pathology ; Medical sciences ; Medicine ; Medicine & Public Health ; Miscellaneous ; Ocular Hypertension - drug therapy ; Ocular Hypertension - pathology ; Ophthalmology ; Pharmaceutical Sciences/Technology ; Prospective Studies ; Retinopathies ; Surgery ; Surgical Oncology ; Timolol - adverse effects ; Timolol - therapeutic use ; Treatment Outcome</subject><ispartof>Eye (London), 2007-02, Vol.21 (2), p.164-168</ispartof><rights>Royal College of Ophthalmologists 2007</rights><rights>2007 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Feb 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c496t-751b6041f71c80ced79688fc0e52d668507dedf21ffb8355c846b3754a9c89ff3</citedby><cites>FETCH-LOGICAL-c496t-751b6041f71c80ced79688fc0e52d668507dedf21ffb8355c846b3754a9c89ff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/sj.eye.6702149$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/sj.eye.6702149$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18548655$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16254590$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martin, E</creatorcontrib><creatorcontrib>Martinez-de-la-Casa, J M</creatorcontrib><creatorcontrib>Garcia-Feijoo, J</creatorcontrib><creatorcontrib>Troyano, J</creatorcontrib><creatorcontrib>Larrosa, J M</creatorcontrib><creatorcontrib>Garcia-Sanchez, J</creatorcontrib><title>A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients</title><title>Eye (London)</title><addtitle>Eye</addtitle><addtitle>Eye (Lond)</addtitle><description>Aim
To compare 6 months of treatment with bimatoprost and timolol in terms of their hypotensive efficacy and secondary effects, including changes in macular thickness and the inflammatory reaction induced in the anterior chamber.
Methods
A prospective, randomized, parallel-group trial performed on 30 eyes of 30 patients per group. The main outcome measure was the difference between the IOP value taken between the baseline visit and the 6-month-visit. Macular thickness determined through optical coherence tomography and anterior chamber inflammation estimated using the laser flare meter was also evaluated. Adverse events were recorded during the study period.
Results
Bimatoprost treatment gave rise to a significantly lower mean IOP than timolol in all follow-up visits as from the first month (
P
<0.05). Bimatoprost achieved high percentage IOP reductions from baseline in a significantly higher proportion of patients (
P
<0.05). Macular thickness and anterior chamber flare failed to vary significantly both between the two groups and within each group during the 6-month evaluation (
P
>0.05).
Conclusions
Bimatoprost 0.03% once daily showed a greater efficacy then timolol 0.05% twice daily in patients with elevated IOP. No significant differences were detected in macular thickness or anterior uveitis using optical coherence tomography and laser flare photometry.</description><subject>Adult</subject><subject>Amides - adverse effects</subject><subject>Amides - therapeutic use</subject><subject>Anterior Chamber - drug effects</subject><subject>Anterior Chamber - pathology</subject><subject>Antihypertensive Agents - adverse effects</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Bimatoprost</subject><subject>Biological and medical sciences</subject><subject>clinical-study</subject><subject>Cloprostenol - adverse effects</subject><subject>Cloprostenol - analogs & derivatives</subject><subject>Cloprostenol - therapeutic use</subject><subject>Glaucoma</subject><subject>Glaucoma and intraocular pressure</subject><subject>Glaucoma, Open-Angle - drug therapy</subject><subject>Glaucoma, Open-Angle - pathology</subject><subject>Humans</subject><subject>Intraocular Pressure - drug effects</subject><subject>Laboratory Medicine</subject><subject>Lipids - adverse effects</subject><subject>Lipids - therapeutic use</subject><subject>Macula Lutea - drug effects</subject><subject>Macula Lutea - pathology</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Miscellaneous</subject><subject>Ocular Hypertension - drug therapy</subject><subject>Ocular Hypertension - pathology</subject><subject>Ophthalmology</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Prospective Studies</subject><subject>Retinopathies</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Timolol - adverse effects</subject><subject>Timolol - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0950-222X</issn><issn>1476-5454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kUtv1DAUhS0EokNhyxJZSLMjqZ34FXZVBRSpEhuQ2EWOc93JkMSD7VSan8M_5ZYJmlVXlny-c1-HkLeclZzV5irtSzhCqTSruGiekQ0XWhVSSPGcbFgjWVFV1c8L8iqlPWMoavaSXHBVIdKwDflzTVUxhTnvqE0JUppgzjR42g2TzeEQQ8qUlaze0odE8zCFMYx0siPYDCjI7Ue6Ox5ChjkND0DB-8FZd_yAjFtGG2neDe7XjJWpnXvq8QvoMNPwTy3QC_G_-RG4H-3iwmTpweYBZ0mvyQtvxwRv1veS_Pj86fvNbXH37cvXm-u7wolG5UJL3ikmuNfcGeag140yxjsGsuqVMpLpHnpfce87U0vpjFBdraWwjTON9_UleX-qizv_XiDldh-WOGPLtuLoqLQWCJUnyOFhUgTfHiIeKh5bztrHQNq0bzGQdg0EDe_Wqks3QX_G1wQQ2K6ATc6OPtrZDenMGSmMkhK5qxOXUJrvIZ7He6L1XytdpcE</recordid><startdate>20070201</startdate><enddate>20070201</enddate><creator>Martin, E</creator><creator>Martinez-de-la-Casa, J M</creator><creator>Garcia-Feijoo, J</creator><creator>Troyano, J</creator><creator>Larrosa, J M</creator><creator>Garcia-Sanchez, J</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20070201</creationdate><title>A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients</title><author>Martin, E ; Martinez-de-la-Casa, J M ; Garcia-Feijoo, J ; Troyano, J ; Larrosa, J M ; Garcia-Sanchez, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c496t-751b6041f71c80ced79688fc0e52d668507dedf21ffb8355c846b3754a9c89ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Amides - adverse effects</topic><topic>Amides - therapeutic use</topic><topic>Anterior Chamber - drug effects</topic><topic>Anterior Chamber - pathology</topic><topic>Antihypertensive Agents - adverse effects</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Bimatoprost</topic><topic>Biological and medical sciences</topic><topic>clinical-study</topic><topic>Cloprostenol - adverse effects</topic><topic>Cloprostenol - analogs & derivatives</topic><topic>Cloprostenol - therapeutic use</topic><topic>Glaucoma</topic><topic>Glaucoma and intraocular pressure</topic><topic>Glaucoma, Open-Angle - drug therapy</topic><topic>Glaucoma, Open-Angle - pathology</topic><topic>Humans</topic><topic>Intraocular Pressure - drug effects</topic><topic>Laboratory Medicine</topic><topic>Lipids - adverse effects</topic><topic>Lipids - therapeutic use</topic><topic>Macula Lutea - drug effects</topic><topic>Macula Lutea - pathology</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Miscellaneous</topic><topic>Ocular Hypertension - drug therapy</topic><topic>Ocular Hypertension - pathology</topic><topic>Ophthalmology</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Prospective Studies</topic><topic>Retinopathies</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Timolol - adverse effects</topic><topic>Timolol - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martin, E</creatorcontrib><creatorcontrib>Martinez-de-la-Casa, J M</creatorcontrib><creatorcontrib>Garcia-Feijoo, J</creatorcontrib><creatorcontrib>Troyano, J</creatorcontrib><creatorcontrib>Larrosa, J M</creatorcontrib><creatorcontrib>Garcia-Sanchez, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Eye (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martin, E</au><au>Martinez-de-la-Casa, J M</au><au>Garcia-Feijoo, J</au><au>Troyano, J</au><au>Larrosa, J M</au><au>Garcia-Sanchez, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients</atitle><jtitle>Eye (London)</jtitle><stitle>Eye</stitle><addtitle>Eye (Lond)</addtitle><date>2007-02-01</date><risdate>2007</risdate><volume>21</volume><issue>2</issue><spage>164</spage><epage>168</epage><pages>164-168</pages><issn>0950-222X</issn><eissn>1476-5454</eissn><coden>EYEEEC</coden><abstract>Aim
To compare 6 months of treatment with bimatoprost and timolol in terms of their hypotensive efficacy and secondary effects, including changes in macular thickness and the inflammatory reaction induced in the anterior chamber.
Methods
A prospective, randomized, parallel-group trial performed on 30 eyes of 30 patients per group. The main outcome measure was the difference between the IOP value taken between the baseline visit and the 6-month-visit. Macular thickness determined through optical coherence tomography and anterior chamber inflammation estimated using the laser flare meter was also evaluated. Adverse events were recorded during the study period.
Results
Bimatoprost treatment gave rise to a significantly lower mean IOP than timolol in all follow-up visits as from the first month (
P
<0.05). Bimatoprost achieved high percentage IOP reductions from baseline in a significantly higher proportion of patients (
P
<0.05). Macular thickness and anterior chamber flare failed to vary significantly both between the two groups and within each group during the 6-month evaluation (
P
>0.05).
Conclusions
Bimatoprost 0.03% once daily showed a greater efficacy then timolol 0.05% twice daily in patients with elevated IOP. No significant differences were detected in macular thickness or anterior uveitis using optical coherence tomography and laser flare photometry.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>16254590</pmid><doi>10.1038/sj.eye.6702149</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-222X |
| ispartof | Eye (London), 2007-02, Vol.21 (2), p.164-168 |
| issn | 0950-222X 1476-5454 |
| language | eng |
| recordid | cdi_proquest_journals_218352774 |
| source | MEDLINE; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Amides - adverse effects Amides - therapeutic use Anterior Chamber - drug effects Anterior Chamber - pathology Antihypertensive Agents - adverse effects Antihypertensive Agents - therapeutic use Bimatoprost Biological and medical sciences clinical-study Cloprostenol - adverse effects Cloprostenol - analogs & derivatives Cloprostenol - therapeutic use Glaucoma Glaucoma and intraocular pressure Glaucoma, Open-Angle - drug therapy Glaucoma, Open-Angle - pathology Humans Intraocular Pressure - drug effects Laboratory Medicine Lipids - adverse effects Lipids - therapeutic use Macula Lutea - drug effects Macula Lutea - pathology Medical sciences Medicine Medicine & Public Health Miscellaneous Ocular Hypertension - drug therapy Ocular Hypertension - pathology Ophthalmology Pharmaceutical Sciences/Technology Prospective Studies Retinopathies Surgery Surgical Oncology Timolol - adverse effects Timolol - therapeutic use Treatment Outcome |
| title | A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T04%3A02%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%206-month%20assessment%20of%20bimatoprost%200.03%25%20vs%20timolol%20maleate%200.5%25:%20hypotensive%20efficacy,%20macular%20thickness%20and%20flare%20in%20ocular-hypertensive%20and%20glaucoma%20patients&rft.jtitle=Eye%20(London)&rft.au=Martin,%20E&rft.date=2007-02-01&rft.volume=21&rft.issue=2&rft.spage=164&rft.epage=168&rft.pages=164-168&rft.issn=0950-222X&rft.eissn=1476-5454&rft.coden=EYEEEC&rft_id=info:doi/10.1038/sj.eye.6702149&rft_dat=%3Cproquest_cross%3E1207769081%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218352774&rft_id=info:pmid/16254590&rfr_iscdi=true |